| Sanofi / Regeneron's Partnership Paying Off Prohost Biotech submits:When Sanofi-Avantis (SNY) made a major endorsement of Regeneron's (REGN) technology in 1997 and signed a drug-development partnership with the company, we asked why? And when the top class pharmaceutical firm has willingly decided to offer Regeneron $160 million a year to develop therapeutic antibodies that they can equally share their revenues, we, again, asked why? We also asked: What did the French giant drug maker expect to get from Regeneron, which it could not itself provide or get from other biotech firms? We satisfied our built-in curiosity as early as a few days after the signature of the cooperative agreement between the two firms. We learned at the right time that Sanofi had fallen in love with Regeneron’s antibody technology and that it expected the small firm to be capable of advancing several antibodies into clinical trials each year through 2017. It was obvious that Sanofi-Aventis decided to pay the costs of developing Regeneron’s drugs because it wanted the small firm to focus on building the therapeutic molecules under no tension that would cause unnecessary delays.Complete Story » seekingalpha.com |
Patient Empowered Care at CTCA - Video Treatment Environment, Health Literacy May Improve Cancer Outcomes feedproxy.google.com |
China Nuokang Bio-Pharmaceutical Provides Update on Product Pipeline (GlobeNewswire) Kaitong Technical Review Completed Dipyridamole Aspirin Onsite Inspection Completed us.rd.yahoo.com |
Artistry Crème LuXury - Video Creme LuXury Combats Intrinsic Causes of Skin Aging with Industry Leading Technology feedproxy.google.com |
Aetna CEO to Retire Aetna Chairman and CEO Ronald A. Williams will step down as CEO next month, to be succeeded by President Mark T. Bertolini. online.wsj.com |